These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 15687325)

  • 1. A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.
    Larsson T; Yu X; Davis SI; Draman MS; Mooney SD; Cullen MJ; White KE
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2424-7. PubMed ID: 15687325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
    Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed.
    Larsson T; Davis SI; Garringer HJ; Mooney SD; Draman MS; Cullen MJ; White KE
    Endocrinology; 2005 Sep; 146(9):3883-91. PubMed ID: 15961556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
    Ichikawa S; Imel EA; Sorenson AH; Severe R; Knudson P; Harris GJ; Shaker JL; Econs MJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4472-5. PubMed ID: 16940445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia.
    Benet-Pagès A; Orlik P; Strom TM; Lorenz-Depiereux B
    Hum Mol Genet; 2005 Feb; 14(3):385-90. PubMed ID: 15590700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
    Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
    J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive.
    Ichikawa S; Lyles KW; Econs MJ
    J Clin Endocrinol Metab; 2005 Apr; 90(4):2420-3. PubMed ID: 15687324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis.
    Garringer HJ; Malekpour M; Esteghamat F; Mortazavi SM; Davis SI; Farrow EG; Yu X; Arking DE; Dietz HC; White KE
    Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E929-37. PubMed ID: 18682534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis.
    Masi L; Gozzini A; Franchi A; Campanacci D; Amedei A; Falchetti A; Franceschelli F; Marcucci G; Tanini A; Capanna R; Brandi ML
    J Bone Joint Surg Am; 2009 May; 91(5):1190-8. PubMed ID: 19411468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.
    Araya K; Fukumoto S; Backenroth R; Takeuchi Y; Nakayama K; Ito N; Yoshii N; Yamazaki Y; Yamashita T; Silver J; Igarashi T; Fujita T
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5523-7. PubMed ID: 16030159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
    Rafaelsen S; Johansson S; Ræder H; Bjerknes R
    BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification.
    Chefetz I; Heller R; Galli-Tsinopoulou A; Richard G; Wollnik B; Indelman M; Koerber F; Topaz O; Bergman R; Sprecher E; Schoenau E
    Hum Genet; 2005 Nov; 118(2):261-6. PubMed ID: 16151858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two novel GALNT3 mutations in familial tumoral calcinosis.
    Garringer HJ; Mortazavi SM; Esteghamat F; Malekpour M; Boztepe H; Tanakol R; Davis SI; White KE
    Am J Med Genet A; 2007 Oct; 143A(20):2390-6. PubMed ID: 17853462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
    Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
    Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
    Frishberg Y; Ito N; Rinat C; Yamazaki Y; Feinstein S; Urakawa I; Navon-Elkan P; Becker-Cohen R; Yamashita T; Araya K; Igarashi T; Fujita T; Fukumoto S
    J Bone Miner Res; 2007 Feb; 22(2):235-42. PubMed ID: 17129170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Familial tumoral calcinosis caused by a novel FGF23 mutation: response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer.
    Lammoglia JJ; Mericq V
    Horm Res; 2009; 71(3):178-84. PubMed ID: 19188744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
    Imel EA; Hui SL; Econs MJ
    J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
    Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
    Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.
    Shah A; Miller CJ; Nast CC; Adams MD; Truitt B; Tayek JA; Tong L; Mehtani P; Monteon F; Sedor JR; Clinkenbeard EL; White K; Mehrotra R; LaPage J; Dickson P; Adler SG; Iyengar SK
    Nephrol Dial Transplant; 2014 Dec; 29(12):2235-43. PubMed ID: 25378588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.